1. Novel Small Molecule Therapies in Rheumatoid Arthritis

3. Introduction

4. Biologic Agents in RA

5. Biologic Agents: MOAs

6. Using Biologics in RA

7. Intracellular Kinases

8. JAK Inhibitors

9. Emerging JAK Inhibitors

10. Transduction in Pairs: JAK/STAT Signaling Pathways

11. Baricitinib: Phase 3 Studies

12. Some Unanswered Questions

13. Tofacitinib Phase 3 Studies

14. Baricitinib Safety: RA-BEAM

15. Tofacitinib and Baricitinib Monotherapy: Similar Results

16. Baricitinib vs ADA: RA-BEAM

17. Earlier Use of JAKs/Biologics

18. Baricitinib Dose Step-Down

19. Common Safety Concerns with DMARDs

20. Baricitinib Safety

21. Herpes Zoster in RA

22. PROs with Baricitinib: RA-BEGIN

23. Filgotinib: JAK 1 Inhibitor

24. ACR20/50/70 Findings: 3 QD Doses

25. PROs: QD vs BID Filgotinib

26. Filgotinib Safety

27. Summary